Related Experiment Video
Updated: Sep 10, 2025

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
Design, Ssynthesis and Ddocking study of 1,2,3-triazole incorporated benzoxazole-oxazole derivatives and evaluation
Adurthi Suryakumari1, Chithaluri Sudhakar2, Bijaya Ketan Sahoo2
1Department of Chemistry, School of Science, GITAM Deemed to be University, Hyderabad, Telangana 502 102, India; BJR Government Degree College (Autonomous), Narayanaguda, Hyderabad, Telangana 500029, India.
Abstract:
The study reports the design and synthesis of a new library of triazole in-corporated benzoxazole oxazole compounds (11a-j) and their in vitro cytotoxic activity evaluation. The structural reliability of the synthesized compounds was confirmed by 1H NMR, 13C NMR, and mass spectral data. We have selected ER-α and CDK2 proteins for molecular docking study of the active compounds to examine their binding interactions. We have also screened the preliminary cytotoxic activity of compounds 11a-j against four human cancer cell lines: MCF-7, A549, Colo-205, and A2780 by the MTT assay with etoposide, a well-known chemotherapy drug, as a control. All the molecules have shown strong binding interactions with A binding affinity of -8.9 to -9.4 kcal/mol with the proteins ER-α and CDK2 using CB-Dock2 online server. In our findings all the compounds demonstrated selective activity whereas four of the synthesized compounds, namely 11a, 11b, 11c, and 11d, have exhibited greater cytotoxic activity against the cancer cells with IC50 ranging from 0.18 to 3.67 μM. Drug likeliness and ADME studies infer that the compounds can be frameworks for the development of anticancer medication.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025